Village Caregiving reports that frontotemporal dementia is a progressive brain disease affecting behavior, speech, and memory ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the ...

Advanced MRI detects early frontotemporal dementia microstructural damage, enabling earlier diagnosis and monitoring of disease progression.

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

In the wake of Bruce Willis' diagnosis, Emma Heming has taken to social media to raise awareness about FTD, a type of dementia that affects behavior, personality, and language. Through her heartfelt ...

An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage ...

Alector’s ambitions for a breakthrough in rare dementia have been upended after its lead drug latozinemab (AL001), partnered ...

Alector Inc. cuts its workforce by nearly 50% following the failure of its dementia drug trial, signalling challenges in the ...